Related by context. All words. (Click for frequent words.) 69 PASI scores 68 nighttime awakenings 67 HbA 1c levels 67 daytime alertness 67 hematologic parameters 67 salivary cortisol 67 pulmonary dysfunction 66 daytime somnolence 66 neuropsychological impairments 66 HbA1C levels 66 urine albumin 66 Symptom severity 66 cecal intubation 65 EDSS scores 65 analgesic medications 65 pyridostigmine 65 depressive symptom 65 timepoints 65 MMSE scores 65 glomerular filtration 65 interpersonal psychotherapy 65 postoperative complication 65 NIHSS score 65 DLQI 65 apneic episodes 65 neutrophil counts 65 daytime drowsiness 65 prospectively stratified 65 postprocedure 64 postoperative mortality 64 serum clusterin levels 64 cerebral oxygenation 64 hypofractionated radiation 64 cardiac autonomic 64 acromegalic patients 64 reflux symptoms 64 inhaled corticosteroid therapy 64 parkinsonian symptoms 64 OAB symptoms 64 virological response 64 PSA nadir 64 transaminase elevations 64 MS relapses 64 untreated OSA 64 titration phase 63 albumin excretion 63 intravenous diuretics 63 transaminase levels 63 HAQ DI 63 metabolic parameters 63 baseline HbA1c 63 psychiatric comorbidities 63 diastolic pressures 63 extrapyramidal symptoms 63 angiographic outcomes 63 cardiopulmonary fitness 63 neurologic outcomes 63 posttreatment 63 glycosylated hemoglobin HbA1c 63 frequent awakenings 63 MADRS score 63 blood Phe levels 63 pharmacodynamic parameters 63 spirometric 63 dosage regimens 63 hemoglobin A1c levels 63 postintervention 63 non menstrual pelvic 63 serum lipid levels 63 intensive statin therapy 63 Clot busting 63 nonpharmacologic 63 QTc intervals 63 morphometric vertebral fractures 63 dose Iluvien 63 aldosterone antagonist 63 systemic hypotension 63 RLS symptoms 63 hypoglycemic events 63 glycated hemoglobin HbA1c 63 interindividual variability 63 d dimer 63 neurodevelopmental outcomes 63 MMSE score 63 neurocognitive functioning 63 thyrotropin levels 63 dopaminergic therapy 63 peak VO2 63 hemodynamic measurements 63 glycemia 63 HRQL 62 serum phosphate levels 62 Adverse effects 62 esophageal motility 62 insulin detemir 62 divalproex sodium 62 NIHSS 62 oxygen saturations 62 glycated hemoglobin levels 62 body habitus 62 platelet inhibition 62 oncologic outcomes 62 treprostinil 62 Postoperatively 62 oral anticoagulant therapy 62 subthreshold depression 62 dose proportionality 62 exploratory endpoints 62 ALT flares 62 MoxDuo TM IR 62 solifenacin 62 certolizumab 62 neurophysiologic 62 electrophysiologic 62 Index CDAI 62 locomotor activity 62 Non inferiority 62 HbA1C 62 antioxidant supplementation 62 intravitreal injections 62 poststroke 62 plasma triglycerides 62 intracerebral haemorrhage 62 VO2 peak 62 methotrexate monotherapy 62 oxycodone CR 62 intracranial stenosis 62 platelet reactivity 62 severe exacerbations 62 XEPLION R 62 psychosocial functioning 62 nonadherence 62 poststroke depression 62 HIV HCV coinfected 62 adrenal function 62 SRBD 62 steroid dexamethasone 62 polysomnography PSG 62 Primary endpoints 62 convergent validity 62 symptomatic VTE 62 nonfasting triglyceride levels 62 neurocognitive function 62 arterial thickening 62 tic severity 62 Baseline characteristics 62 Visual acuity 62 serum cortisol 62 symptom severity 62 tapentadol ER 62 comorbid disorders 62 Platelet counts 61 CLBP 61 serum urate 61 glycosylated hemoglobin levels 61 Hb A1C 61 nocturnal awakenings 61 left ventricular diastolic 61 foveal thickness 61 SGRQ 61 pulmonary capillary wedge 61 concomitant medications 61 atypical antipsychotic medications 61 psychosocial variables 61 WOMAC pain 61 Fibromyalgia Impact Questionnaire 61 moderate renal impairment 61 dosing frequency 61 IOP lowering 61 HbA 1C 61 diagnosing ADHD 61 intravascular hemolysis 61 hematological toxicity 61 DAS# scores 61 APTIVUS r 61 sleep apneas 61 postoperative chemotherapy 61 metabolite concentrations 61 sedating antihistamine 61 plasma cortisol 61 severe hypoglycaemia 61 urolithiasis 61 resynchronization therapy 61 perioperative morbidity 61 UPDRS motor 61 trials RCTs 61 virologic responses 61 Insulin sensitivity 61 serum sodium levels 61 Triglyceride levels 61 Pharmacokinetic parameters 61 Fasting glucose 61 postoperative morbidity 61 interrater reliability 61 antihypertensive therapy 61 oxygen desaturation 61 hsCRP levels 61 PLMS 61 Cortisol levels 61 eculizumab therapy 61 hepatic enzymes 61 plasma creatinine 61 NNT = 61 intracranial hemorrhage ICH 61 NYHA functional class 61 autonomic dysfunction 61 intraobserver 61 CORE OM 61 Heavy menstrual bleeding 61 serum urate levels 61 troponin T 61 Sleep disturbances 61 NYHA classification 61 corticosteroid dose 61 pharmacological therapy 61 haemodynamic 61 triglyceride concentrations 61 hemoglobin A1c HbA1c 61 Coronary CTA 61 serum vitamin D 61 venlafaxine XR 61 neurodevelopmental outcome 61 ICD therapy 61 EDSS score 61 Preterm infants 61 conditional logistic regression 61 myocardial reperfusion 61 PANSS scores 61 liver histology 61 attain statistical significance 61 pharmacokinetic characteristics 61 chronic LBP 61 HRQoL 61 tolerability profiles 61 Stent thrombosis 61 NATRECOR R 61 clinically meaningful improvement 61 CIMZIA ™ 61 incontinence episodes 61 Negative Symptoms 60 dexmedetomidine 60 Ceplene/IL-2 60 p = #.# [003] 60 inhospital mortality 60 Subgroup analyzes 60 aminotransferases 60 nicardipine 60 riociguat 60 postdischarge 60 nocturnal hypoglycaemia 60 antidepressant efficacy 60 ADCS CGIC 60 PCWP 60 preintervention 60 hemorrhagic complications 60 symptom exacerbation 60 airway narrowing 60 therapeutic regimens 60 suboptimal adherence 60 venous thromboembolic disease 60 intraocular pressure IOP 60 Viral load 60 perinatal asphyxia 60 Fasting plasma glucose 60 Febrile neutropenia 60 neurocognitive deficits 60 urate levels 60 asthma exacerbations 60 ELBW infants 60 carotid IMT 60 rhinoconjunctivitis 60 Depressive symptoms 60 neurosensory 60 Secondary efficacy endpoints 60 residual platelet reactivity 60 HbA1c levels 60 salivary flow 60 Tekamlo 60 clevidipine 60 psychiatric comorbidity 60 carotid artery blockage 60 venous thromboembolism prophylaxis 60 Serum creatinine 60 serum calcium levels 60 nondepressed 60 peak plasma concentrations 60 GH deficiency 60 NIH CPSI 60 RSV hospitalizations 60 Rigorous scientific 60 systolic dysfunction 60 nasal symptom 60 thromboprophylaxis 60 VTE prophylaxis 60 erection hardness 60 SCIg 60 artery stenosis 60 interobserver 60 alicaforsen enema 60 tapentadol IR 60 demonstrated clinically meaningful 60 rt PA 60 lymphocyte counts 60 revascularization procedures 60 Erectile function 60 subjective sleepiness 60 dose titration 60 hepatic function 60 myocardial viability 60 COPD exacerbation 60 randomized controlled trials RCTs 60 AST ALT 60 INVEGA ® 60 antipsychotic prescribing 60 adenotonsillectomy 60 viral titers 60 intra ocular pressure 60 posttransplant 60 systemic corticosteroid 60 brachial artery flow 60 A1c levels 60 probiotic supplementation 60 baseline A1C 60 relapsed MM 60 daytime sleepiness 60 eyelash prominence 60 INVEGA ® SUSTENNA TM 60 dosing cohort 60 TMP SMX 60 generalized epilepsy 60 ejaculatory function 60 lipid lowering agents 60 status epilepticus 60 statin monotherapy 60 Crohn Disease Activity 60 pharmacokinetic PK profile 60 leucopenia 60 CONCERTA ® 60 meta regression 60 tumor histology 60 cyclic HMB 60 inhaled glucocorticoids 60 symptomatic aortic stenosis 60 quetiapine XR 60 depressive symptomatology 60 MAS XR 60 dose statin therapy 60 baseline LDH 60 pegylated IFN 60 maximal doses 60 serum creatinine levels 60 blood glucose concentrations 60 tissue oxygenation 60 carotid stenosis 60 sociodemographic factors 60 elevated IOP 59 Skin sterol 59 immunosuppression therapy 59 cognitive domains 59 prodromal symptoms 59 guideline concordant 59 angiographic restenosis 59 multivariable analyzes 59 mean ± SEM 59 definite stent thrombosis 59 methacholine challenge 59 hemoglobin A1C 59 hypovolemia 59 weekly CSBMs 59 APTIVUS R 59 radiographic outcomes 59 serum bicarbonate 59 interpersonal psychotherapy IPT 59 serum aminotransferase levels 59 hepatic lesions 59 UPDRS scores 59 CT perfusion 59 intermittent hypoxia 59 spontaneous bowel movements 59 opioid naïve 59 eszopiclone 59 NAbs 59 virologic response 59 overactive bladder symptoms 59 comorbid depression 59 eNO 59 hyperoxia 59 pulmonary exacerbation 59 orthostatic 59 BEXXAR Therapeutic Regimen 59 oral corticosteroid 59 interferon ribavirin 59 haematologic 59 chest radiographs 59 atrioventricular block 59 urodynamic parameters 59 androgen excess 59 genotypic resistance 59 EDARBI 59 ACTEMRA TM 59 elevated creatinine 59 tolterodine ER 59 ionotropic 59 dose proportional pharmacokinetics 59 neuropsychiatric symptoms 59 ratio ICER 59 corticosterone levels 59 overnight polysomnography 59 transient insomnia 59 oral anticoagulation 59 Global Impression CGI 59 potent antiretroviral therapy 59 TMC# r 59 EXJADE 59 bolus dose 59 euthymic patients 59 postural stability 59 CI -#.# 59 antiarrhythmic drug 59 Interrater reliability 59 aldosterone antagonists 59 Brief Psychiatric 59 apnea hypopnea 59 interobserver reliability 59 ski lls 59 DMARD therapy 59 periodically reassessed 59 aromatase inhibitor therapy 59 analgesic efficacy 59 serum PTH 59 medication nonadherence 59 postoperative hemorrhage 59 epidural analgesia 59 ejection fractions 59 actigraphy 59 perioperatively 59 HbA 1c 59 Tumor Response 59 Hypotension 59 fasting plasma glucose FPG 59 atherosclerotic renal artery stenosis 59 aspirin clopidogrel 59 HER2 expression 59 Generalized anxiety disorder 59 obstructive CAD 59 inhaled budesonide 59 neuromotor 59 perceptual reasoning 59 symptomatic intracranial 59 NPH insulin 59 Daytime sleepiness 59 hemostatic efficacy 59 AGILECT R 59 limiting generalizability 59 euthymic 59 oral FTY# 59 polytherapy 59 virological suppression 59 intima media thickness 59 nausea dizziness vomiting 59 antihypertensive medications 59 atherogenic dyslipidemia 59 ginkgo extract 59 mania hypomania 59 HAM D# 59 HBeAg seroconversion 59 VADT 59 pharmacologic treatments 59 retinal thickness 59 neurologic sequelae 59 L PPDS 59 hyperalgesia 59 comorbid illnesses 59 QALE 59 procalcitonin 59 premenopause 59 hemodynamic parameters 59 albumin excretion rate 59 Kaplan Meier curves 59 nonvertebral fracture 59 allodynia 59 serum potassium 59 pulmonary exacerbations 59 chiropractic manipulation 59 Visual Analogue Scale VAS 59 serum lipid 59 acoustic startle 59 postoperative AF 59 polysomnogram 59 receiving XGEVA 59 YMRS 59 paricalcitol 59 treatment emergent AEs 59 topical NSAIDs 59 creatinine levels 59 somatic symptoms 59 Ejection Fraction 59 perfusion defects 59 Avandia Actos 59 Spinal manipulation 59 inflammatory biomarkers 59 Meta analyzes 59 dose escalation phase 59 UPPP 59 arterial oxygen saturation 59 symptomatic NOH 59 mg Pycnogenol 59 hypoglycemic episodes 59 HIV tropism 59 posttest 59 TEAEs 59 depression suicidal ideation 59 #q# deletion syndrome 59 nocturnal hypoglycemia 59 cortisol secretion 59 β blockers 59 MBCT 59 mesalamine granules 59 Endothelial function 59 triacylglycerol concentrations 59 OSAHS 59 ADCS ADL 59 Montgomery Asberg Depression 59 adverse cytogenetics 59 INVEGA ™ 59 cold pressor test 59 perinatal outcomes 58 cerebral angiography 58 loop diuretics 58 macrovascular events 58 QTcF 58 urinary cortisol 58 decrements 58 desvenlafaxine succinate 58 proton MR spectroscopy 58 olanzapine LAI 58 Logistic regression analysis 58 neutropaenia 58 neurologic symptoms 58 postprandial blood glucose 58 unresectable HCC 58 recurrent miscarriage 58 Chronic insomnia 58 antiemetics 58 pulmonary artery banding 58 bezafibrate 58 serum concentrations 58 inotropes 58 Withdrawal symptoms 58 sociodemographic characteristics 58 BoNTA 58 antiangiogenic agents 58 EORTC QLQ C# 58 tacrolimus ointment 58 atrial tachyarrhythmias 58 Lipitor #mg 58 ADAS cog 58 acute ischemia 58 hemoglobin concentrations 58 ALSFRS R 58 salmeterol fluticasone 58 orthostatic hypotension 58 nasal obstruction 58 KRAS status 58 coronary revascularization procedures 58 BEXXAR therapeutic regimen 58 estimated GFR 58 dizziness nausea diarrhea 58 #mg/day [001] 58 p = .# [002] 58 CK # plasma concentrations 58 serum homocysteine 58 intravenous CK # 58 BPS IC 58 oral antidiabetes 58 prolactin elevation 58 fluticasone salmeterol 58 hepatorenal syndrome 58 OnDose TM 58 unruptured aneurysm 58 perioperative complications 58 antitumor efficacy 58 antibody titer 58 doxorubicin docetaxel 58 hypoperfusion 58 vertigo dizziness 58 clinically meaningful improvements 58 non aspirin NSAIDs 58 cortical atrophy 58 arterial stiffening 58 Complication rates 58 CDAI score 58 polyp detection 58 concomitant AEDs 58 Mood disorders 58 nasopharyngitis headache 58 hyperprolactinemia 58 hepatic fibrosis 58 affective psychoses 58 Homocysteine levels 58 antithrombotic therapy 58 LV dysfunction 58 symptom flare ups 58 thrombotic complications 58 hyper IgE syndrome 58 Genetic predisposition 58 dyspnoea 58 CANCIDAS 58 plasma pharmacokinetics 58 alteplase 58 NATRECOR ® 58 alanine aminotransferase ALT 58 intracranial hypertension 58 gait disturbances 58 nasal airflow 58 NUCYNTA ™ 58 reinfarction 58 Myelosuppression 58 mealtime glucose 58 headache nausea dizziness 58 Inventory BPI 58 Parkinsonian symptoms 58 tipranavir ritonavir 58 buprenorphine naloxone 58 arterial thromboembolic events 58 homocysteine concentrations 58 hematologic toxicity 58 vaginal progesterone gel 58 Oral corticosteroids 58 Chronic ITP 58 nocturnal hemodialysis 58 MELD scores 58 TNF antagonist 58 antiepileptic drugs AEDs 58 lymphocyte count 58 generalizability 58 hypoglycaemic episodes 58 serum bilirubin 58 cerebral perfusion 58 cystoscopic 58 ragweed allergic 58 intermittent dosing 58 stone formers 58 ETDRS 58 pharmacological therapies 58 serum phosphate 58 acetabular dysplasia 58 obstructive sleep 58 myopathy rhabdomyolysis 58 physiologic responses 58 androgen suppression 58 clomipramine 58 asymptomatic PAD 58 clinically meaningful reductions 58 MIRAPEX ER 58 carbohydrate absorption 58 oral prednisolone 58 chasers motivations 58 Pneumococcal vaccination 58 serum phosphorous 58 radiographic progression 58 Chronically ill patients 58 cognitive behavioral therapies 58 GERD symptom 58 isolated systolic hypertension 58 FXIII 58 vitamin D inadequacy 58 1mg dose 58 Suicidal tendencies 58 Stretta procedure 58 linear pharmacokinetics 58 allogeneic HSCT 58 abnormal cytology 58 hypochondriasis 58 linaclotide treated 58 SBM frequency 58 oral antidiabetes drugs 58 #.#/#.# mmHg [001] 58 inhaling nitric oxide 58 coronary revascularizations 58 HUMIRA adalimumab 58 inhaled iloprost 58 corticosteroid therapy 58 Cognitive impairment 58 sweat chloride 58 intravenous cyclophosphamide 58 periprocedural 58 tegaserod 58 serum triglyceride levels 58 bronchial hyperresponsiveness 58 lipid profiles 58 psychopathological symptoms 58 MACUGEN 58 nasal allergy symptoms 58 somatoform disorders 58 bloodpressure 58 thiopurine 58 serum estradiol 58 hypertension diabetes mellitus 58 unpaired t 58 abdominal girth 58 affective psychosis 58 antiviral efficacy 58 headache dizziness fatigue 58 silent myocardial ischemia 58 perioperative mortality 58 tipranavir r 58 tele ICU 58 urodynamic 58 impaired cognition 58 symptomatic hyponatremia 58 antiplatelet therapies 58 Severity Index PASI 58 STEP BD 58 premorbid 58 hemodilution 58 anagrelide 58 gastric pH 58 PMS symptoms 58 CIN3 58 Orthostatic hypotension 58 pentoxifylline 58 hypersomnia 58 gastric acidity 58 QTc prolongation 58 iPTH 58 Pulmonary rehabilitation 58 plasma leptin 58 anticholinergic drugs 58 TNSS 58 KDOQI 58 SUSTENNA TM 58 EGFR expression 58 antidiabetic medication 58 Preoperatively 58 Disordered eating 57 TPV r 57 attention-deficit/hyperactivity disorder ADHD 57 SSRI SNRI 57 Y BOCS 57 Calcium intake 57 antidiabetic medications 57 coronary stenosis 57 nondiabetic patients 57 recurrent ischemia 57 DETROL LA 57 Postoperative 57 ofpatients 57 nonmetastatic prostate cancer 57 SpHb monitoring 57 oral corticosteroids 57 recurrent venous thromboembolism 57 LDB CPR 57 prednisone prednisolone 57 orofacial clefts 57 Apgar scores 57 coronary CTA 57 trastuzumab Herceptin ® 57 seroprotection 57 ARB telmisartan 57 urinary calcium excretion 57 growth hormone secretion 57 induced ischemia 57 EEG readings 57 extrapyramidal symptoms EPS 57 prolactin levels 57 REYATAZ ritonavir 57 Cronbach alpha 57 GnRH agonists 57 habitual snorers 57 gemifloxacin 57 Virologic failure 57 TURBT 57 tolvaptan 57 T1DM 57 mRS 57 Excessive daytime sleepiness 57 hypercholesterolaemia 57 internalizing behaviors 57 antibiotic regimens 57 KAPIDEX 57 adjuvant therapies 57 Acute Ischemic Stroke 57 colorectal adenoma 57 preoperative chemotherapy 57 postdose 57 Butrans 57 neurobehavioural 57 rimonabant #mg 57 RLS sufferers 57 cerebrovascular events 57 #mg dose [002] 57 submaximal 57 aspartate aminotransferase AST 57 amisulpride 57 antithrombotic therapies 57 noncardiovascular mortality 57 recurrent tonsillitis 57 cosmesis 57 corneal thickness 57 virological failure 57 LAGB 57 EVIZON 57 sedating medications 57 decompensated heart failure 57 thorough QT 57 pediatric bipolar disorder 57 carcinomatosis 57 oncological outcomes 57 dyslipidaemia 57 triglyceride concentration 57 Fluid retention 57 teriflunomide 57 underdiagnosis 57 HPA axis suppression 57 azilsartan medoxomil 57 glycated hemoglobin 57 elevated ALT 57 urate lowering therapy 57 prolonged QT interval 57 coronary calcification 57 COPD exacerbations 57 Uncontrolled hypertension 57 reactogenicity 57 thromboembolic complications 57 electrical cardioversion 57 neurologic abnormalities 57 somatic complaints 57 placebo controlled studies 57 biologic DMARDs 57 baseline PASI 57 dosimetric 57 serum sodium 57 comorbid psychiatric 57 #mmHg [001] 57 Serious adverse reactions 57 Kaplan Meier estimate 57 airflow obstruction 57 beta blocker therapy 57 vessel dilation 57 coronary stenoses 57 proliferative diabetic retinopathy 57 postoperative infections 57 Logistic regression 57 Provent Therapy 57 HER2 overexpression 57 anemia hemoglobin 57 PLMs 57 Subgroup analysis 57 wrist actigraphy 57 akinesia 57 meta analytic 57 Multivariate logistic regression 57 sustained virologic response 57 psychiatric morbidity 57 plasma homocysteine 57 PRADAXA 57 diabetic polyneuropathy 57 nutrient supplementation 57 psychoeducation 57 allergic airway inflammation 57 T2 lesions 57 serum HBV DNA 57 univariate analyzes 57 peri procedural 57 hemodialysis patients 57 Trouble Tracker 57 chronicity 57 urinary symptoms 57 Hemoglobin A1c 57 cerebral oxygen saturation 57 racemic albuterol 57 alexithymia 57 prognostic variables 57 aneurysmal subarachnoid hemorrhage 57 lipid lowering medication 57 Perforomist Inhalation Solution 57 decubitus ulcers 57 levodopa therapy 57 plasma renin 57 thyroid hormone levels 57 tasimelteon 57 postoperative pulmonary 57 thrombolytic agents 57 colonoscopic 57 conventional DMARDs 57 immunosuppressive regimens 57 Decitabine 57 fasting insulin 57 reperfusion therapy 57 newer atypical antipsychotics 57 PASI score 57 HSCT 57 gp# vaccine 57 nonexposed 57 polysomnographic 57 antimicrobial prophylaxis 57 conventional antipsychotics 57 elevated bilirubin 57 paclitaxel eluting stents 57 achieving PASI 57 expiratory flow 57 somatostatin analogs 57 malabsorptive 57 antimuscarinic 57 peripheral insulin sensitivity 57 SUVmax 57 NIASPAN 57 Aortic stenosis 57 irregular menses 57 viral kinetics 57 unfavorable cytogenetics 57 mmHg diastolic 57 dizziness nausea headache 57 IELT 57 Helicobacter infection 57 metformin monotherapy 57 hawthorn extract 57 impulsiveness hyperactivity 57 warfarin dosage 57 multivariable adjustment 57 CLA supplementation 57 mild renal insufficiency 57 micronutrient supplementation 57 atherothrombotic disease 57 neurologic impairment 57 hypoglycemia unawareness 57 QT interval prolongation 57 allergen immunotherapy 57 Exacerbations 57 nonobstructive CAD 57 CPAP therapy 57 EQUETRO 57 tDCS 57 procedural sedation 57 PSA kinetics 57 methotrexate therapy 57 perfusion MRI 57 macrolide antibiotic 57 cellularity 57 abnormal ejaculation 57 inpatient hospitalizations 57 oxycodone IR 57 PLX STROKE targeting 57 generalisability 57 CHD CVD 57 magnesium intake 57 adjunctive ABILIFY 57 oral naltrexone 57 tracheal intubation 57 leukocyte count 57 mean baseline HbA1c 57 TNF alpha inhibitor 57 Platinol ® cisplatin 57 inhospital 57 fasting triglyceride levels 57 Effexor venlafaxine 57 ULTRAM ER 57 urinary oxalate 57 chronic prostatitis chronic 57 octreotide LAR 57 hip BMD 57 urinary N telopeptide 57 ICD shocks 57 renal artery stenosis 57 MACCE 57 ulcer healing 57 myocardial ischaemia 57 disordered breathing 57 smoldering multiple myeloma 57 STRIDE PD 57 acute respiratory tract infections 57 CVD mortality 57 plasma folate 57 intima media thickness IMT 57 GERD symptoms 57 postnatally 57 hematopoietic cancers 57 β blocker 57 Hematologic toxicity 57 pulmonary arterial 57 ATACAND 57 FluCAM arm 57 hyperphenylalaninemia HPA due 57 placebo controlled clinical trials 57 Pfizer Aricept 57 chlorthalidone 57 dobutamine 57 endoscopic sinus surgery 57 akinetic mutism 57 CHD mortality 57 preterm newborns 57 curability 57 endometrial thickness 57 lispro alone 57 severe hepatic dysfunction 57 methylnaltrexone tablet 57 dose colchicine 57 acetazolamide